CAR-T cell engineering by Mechanical Activation for Immunotherapy Applications

Important results from the project

CAR-T cell therapy uses genetically modified T cells to target and destroy cancer cells but faces challenges that delay treatment and limit accessibility. Our project aimed to overcome these hurdles and enhance CAR-T cell production efficiency. We developed a new method to activate and engineer T cells more efficiently using a biocompatible material, significantly improving the process and reducing the time needed to produce CAR-T cells.

Expected long term effects

Our project successfully developed a biocompatible material that enhances the activation and engineering of T cells, reducing CAR-T cell production time. This advancement leads to faster, safer, and more efficient CAR-T cell therapies. Expected effects include quicker treatment initiation, improved patient outcomes, and increased accessibility to this life-saving therapy. Our innovative approach has the potential to significantly advance cancer treatment and benefit more patients.

Approach and implementation

** Denna text är maskinöversatt ** Our project improved CAR-T-cellterapi by improving T-cell activation and production of CAR-T-celler with biocompatible materials. We developed a new polymer that improved efficiency and reduced reliance on animal-produced antibodies, in line with sustainability goals. This advance addressed key challenges, speeding up production and increasing patient access. Successful implementation strengthens the resilience of healthcare systems and sets a new standard for safe, effective and accessible cancer treatments.